ChiCTR2300072318 版本V1.0 版本创建时间2023/06/09 14:49:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072318 

最近更新日期:

Date of Last Refreshed on:

2023-06-09 14:48:59 

注册时间:

Date of Registration:

2023-06-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

三叉神经微球囊压迫扩张术后恶心、呕吐的机制研究及预防用药

Public title:

Study on the mechanism of nausea and vomiting after percutaneous balloon compression for trigeminal neuralgia and preventative drugs

注册题目简写:

English Acronym:

研究课题的正式科学名称:

三叉神经微球囊压迫扩张术后恶心、呕吐的机制研究及预防用药

Scientific title:

Study on the mechanism of nausea and vomiting after percutaneous balloon compression for trigeminal neuralgia and preventative drugs

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郜丽琴 

研究负责人:

郜丽琴 

Applicant:

Gao Liqin 

Study leader:

Gao Liqin 

申请注册联系人电话:

Applicant telephone:

+86 182 0321 2623

研究负责人电话:

Study leader's
telephone:

+86 182 0321 2623

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18203212623@163.com

研究负责人电子邮件:

Study leader's E-mail:

18203212623@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市新华区和平西路215号

研究负责人通讯地址:

河北省石家庄市新华区和平西路215号

Applicant address:

215 Heping Road West, Shijiazhuang, Hebei, China

Study leader's address:

215 Heping Road West, Shijiazhuang, Hebei, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北医科大学第二医院

Applicant's institution:

The Second Hospital of Hebei Medical University

研究负责人所在单位:

河北医科大学第二医院

Affiliation of the Leader:

The Second Hospital of Hebei Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-R130

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北医科大学第二医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of the Second Hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-05-26 00:00:00

伦理委员会联系人:

安雯婷

Contact Name of the ethic committee:

Wenting An

伦理委员会联系地址:

河北省石家庄市新华区和平西路215号

Contact Address of the ethic committee:

215 Heping Road West, Shijiazhuang, Hebei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 311 6600 2811

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北医科大学第二医院

Primary sponsor:

The Second Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

河北省石家庄市新华区和平西路215号

Primary sponsor's address:

215 Heping Road West, Shijiazhuang, Hebei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院

具体地址:

河北省石家庄市新华区和平西路215号

Institution
hospital:

The Second Hospital of Hebei Medical University

Address:

215 Heping Road West, Shijiazhuang, Hebei, China

经费或物资来源:

博士课题

Source(s) of funding:

PhD topic

研究疾病:

三叉神经痛  

Target disease:

trigeminal neuralgia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

回顾性比较球囊压迫术与射频热凝术治疗三叉神经痛恶心、呕吐发生情况; 三叉神经微球囊压迫扩张术后恶心、呕吐的机制研究及预防用药  

Objectives of Study:

To compare the nausea and vomiting of percutaneous radiofrequency thermocoagulation (PRT) and percutaneous balloon compression (PBC) for trigeminal neuralgia (TN). Study on the mechanism of nausea and vomiting after percutaneous balloon compression for trigeminal neuralgia and preventative drugs

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

同时符合以下条件 (1)符合原发性三叉神经痛诊断标准; (2)行头颅MRI检查除外占位; (3)50岁≤年龄≤85岁 (4)7分≤VAS评分≤10分

Inclusion criteria

All the patients were selected based on the following criteria: (1) primary TN based on symptoms described by the International Headache Society Classification; (2)normal brain magnetic resonance imaging findings; (3)Age:50~85years (4) a pain visual analog scale (VAS) score over 7/10 and with a poor quality of life because of the pai3n

排除标准:

(1)不能配合的患者; (2)出凝血异常

Exclusion criteria:

(1)Patients who can not cooperate (2)abnormal coagulation function

研究实施时间:

Study execute time:

From 2023-06-08 00:00:00 To 2024-04-26 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-08 00:00:00 To 2024-04-26 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

50

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

观察组A (咪达唑仑+阿托品)

样本量:

50

Group:

observation group A (midazolam + atropine)

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

观察组B (咪达唑仑+盐酸甲氧氯普胺)

样本量:

50

Group:

observation group B (midazolam + metoclopramide hydrochloride)

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

观察组C (咪达唑仑+苯海拉明)

样本量:

50

Group:

observation group C (midazolam + diphenhydramine)

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

观察组D (咪达唑仑+地塞米松)

样本量:

50

Group:

observation group D (midazolam + dexamethasone)

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

恶心呕吐

指标类型:

主要指标

Outcome:

nausea and vomiting

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS评分

指标类型:

次要指标

Outcome:

VAS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

单纯疱疹

指标类型:

次要指标

Outcome:

herpes simplex

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头痛

指标类型:

次要指标

Outcome:

Headache

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜反射

指标类型:

次要指标

Outcome:

corneal reflex

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血5羟色胺

指标类型:

主要指标

Outcome:

5-hydroxytryptamine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

P物质

指标类型:

主要指标

Outcome:

substance P

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

多巴胺

指标类型:

主要指标

Outcome:

dopamine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

组胺

指标类型:

主要指标

Outcome:

histamine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文支持材料

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

surpporting materials for the artical

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-06-09 14:48:59